Pimodivir

DRUG4 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC

Conditions

H7N9 Subtype of Influenza A VirusHealthyHepatic ImpairmentKidney Failure, Chronic

Phase 1

A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults

CompletedNCT03768609

Janssen-Cilag International NVHealthy

Start: 2018-12-06End: 2019-03-12Updated: 2019-04-29

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

CompletedNCT03816631

Janssen-Cilag International NVHepatic Impairment

Start: 2019-05-28End: 2020-04-27Updated: 2025-02-03

A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment

TerminatedNCT03947814

Janssen-Cilag International NVKidney Failure, Chronic

Start: 2019-07-02End: 2020-09-09Updated: 2025-02-03

Unknown Phase

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

Janssen Research & Development, LLCH7N9 Subtype of Influenza A Virus

Updated: 2020-10-28